SCHEMBL30656858

SCHEMBL30656858

COCCCn1cnc2ccc(N)cc2c1=O

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TNF P01375 2/20 0.65
▸ P2RX3 P56373 2/20 0.49
▸ POLB P06746 1/20 0.46
▸ MAPT P10636 4/20 0.46
▸ HSD17B10 Q99714 2/20 0.46
▸ LMNA P02545 2/20 0.46
▸ NPC1 O15118 2/20 0.46
▸ RAB9A P51151 2/20 0.46
▸ SMN1; SMN2 Q16637 2/20 0.46
▸ MEN1 O00255 2/20 0.46
▸ KMT2A Q03164 2/20 0.46
▸ KDM4E B2RXH2 1/20 0.46
▸ ALDH1A1 P00352 1/20 0.46
▸ GLA P06280 1/20 0.46
▸ GAA P10253 1/20 0.46
▸ HPGD P15428 1/20 0.46
▸ ATM Q13315 1/20 0.46
▸ NPSR1 Q6W5P4 1/20 0.46
▸ L3MBTL1 Q9Y468 1/20 0.46
▸ HTT P42858 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24166489 1.00 TNF (0.65) TNFP2RX3POLBMAPTHSD17B10
SCHEMBL24165915 0.92 TNF (0.61) TNFP2RX3POLBLMNARAB9A
SCHEMBL30656849 0.92 TNF (0.61) TNFP2RX3POLBLMNARAB9A
SCHEMBL30656837 0.85 TNF (0.69) TNFP2RX3MAPTHSD17B10LMNA
SCHEMBL24166075 0.85 TNF (0.69) TNFP2RX3MAPTHSD17B10LMNA
SCHEMBL24165897 0.82 TNF (0.65) TNFP2RX3POLBLMNARAB9A
SCHEMBL30656806 0.82 TNF (0.65) TNFP2RX3POLBLMNARAB9A
SCHEMBL24166042 0.82 TNF (0.61) TNFP2RX3POLBMAPTHSD17B10
SCHEMBL24166094 0.81 TNF (0.57) TNFP2RX3POLBMAPTLMNA
SCHEMBL30656791 0.81 TNF (0.57) TNFP2RX3POLBMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12528777-B2 Quinazolinones derivatives for treatment of non-alcoholic fatty liver disease, preparation and use thereof COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2026-01-20 — — US disclosed
US-20230357165-A1 QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2023-11-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230357165-A1 QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF ATG7, GOT1, LIPC TNF 4408/4885P2RX3 4659/4885POLB 3444/4885
US-12528777-B2 Quinazolinones derivatives for treatment of non-alcoholic fatty liver disease, preparation and use thereof ATG7, GOT1, ULK1 TNF 4482/4885P2RX3 4456/4885POLB 2856/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback